Appili Therapeutics to Receive $2.8M from Atlantic Canada Opportunities Agency

Appili LogoAppili Therapeutics, Inc., a Halifax, Nova Scotia, Canada-based anti-infective drug development company, will be receiving $2.8m in funding.

The Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF), provided the financial resource.

The company intends to use the funds to take its first drug, ATI-1501, through clinical trials to be ready for market approval.

Led by Kevin Sullivan, CEO, Appili Therapeutics is advancing ATI-1501, a taste-masked, oral antibiotic that treats anaerobic infections like Clostridium difficile. The antibiotic has been optimized to improve palatability, which should reduce issues with non-compliance. Once ingested, ATI-1501 kills anaerobic bacteria by interfering with their DNA, leading to bacterial cell death and clears up the infection.
The company plans to take the antibiotic into clinical trials this year and is presently manufacturing the clinical batch of ATI-1501 to good manufacturing practices (GMP), the standard required by the Health Canada and the U.S. Food and Drug Administration (FDA).

Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health.

FinSMEs

20/02/2017

Join the discussion